🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hamburg
Clinical trial register · Germany

Clinical Trials in Hamburg, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 49 Dresden 33 Hamburg 33 Heidelberg 27 Essen 22
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Universitätsklinikum Hamburg-Eppendorf74 AstraZeneca56 Janssen Research & Development, LLC33 Eli Lilly and Company30 Novartis Pharmaceuticals26 Clear sponsor filter
Site location
Berlin49 Dresden33 Hamburg33 Heidelberg27 Essen22
All 99 locations
Target enrolment
to

Trials with a site in Hamburg

33 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186Multiple Myeloma
DrugsRamantamig·Teclistamab
Janssen Research & Development, LLC
Phase 3
700
Freiburg im Breisgau, Hamburg, Tübingen
2026-05-31
Recruiting
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
NCT07321873Arthritis, Psoriatic
Janssen Research & Development, LLC
Phase 2
240
Bad Bentheim, Berlin, Cottbus, Hamburg, Heidelberg, Mainz, Remscheid, Witten
2026-01-15
Recruiting
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946Prostatic Neoplasms, Castration-Resistant
DrugsPasritamig·Prednisone/Prednisolone·Docetaxel
Janssen Research & Development, LLC
Phase 3
800
Dresden, Duisburg, Essen, Hamburg, München, Nürtingen
2025-12-19
Recruiting
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
NCT07230691Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Observational
380
Aschaffenburg, Bielefeld, Bochum, Chemnitz, Cologne, Düsseldorf, Essen, Hamburg
2025-12-03
Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443Metastatic Castration-resistant Prostatic Neoplasms
DrugsJNJ-87189401·Pasritamig
Janssen Research & Development, LLC
Phase 3
1,203
Braunschweig, Duisburg, Düsseldorf, Essen, Frankfurt am Main, Hamburg, Heidelberg, München
2025-09-02
Recruiting
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222Leukemia, Myeloid, Acute
DrugsBleximenib·Azacitidine·Venetoclax
Janssen Research & Development, LLC
Phase 3
600
Augsburg, Cologne, Dresden, Frankfurt, Freiburg im Breisgau, Hamburg, Heidelberg, Kiel
2025-06-04
Active, closed
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
NCT06878404Arthritis, Psoriatic
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
552
Bad Bentheim, Berlin, Dresden, Freiburg im Breisgau, Hamburg, Herne, Langenau, Minden
2025-02-21
Recruiting
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
NCT06807424Arthritis, Psoriatic
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
750
Berlin, Cologne, Dresden, Freiburg im Breisgau, Hamburg, Herne, Langenau, Ratingen
2025-01-09
Active, closed
Nipocalimab in Moderate to Severe Sjogren's Disease
NCT06741969Sjogrens Syndrome
DrugNipocalimab
Janssen Research & Development, LLC
Phase 3
655
Cologne, Dresden, Erlangen, Freiburg im Breisgau, Hamburg, Hanover, Herne, München
2024-12-04
Recruiting
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
NCT06663332Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
DrugGuselkumab
Janssen Research & Development, LLC
Phase 3
196
Hamburg, Sankt Augustin
2024-10-29
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786Colorectal Neoplasms
DrugsLeucovorin calcium/Levoleucovorin·Erbitux·Amivantamab·Irinotecan
Janssen Research & Development, LLC
Phase 3
1,000
Berlin, Dresden, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Heidelberg, Mainz
2024-10-18
Active, closed
A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT06425991Multiple Myeloma
DrugTeclistamab
Janssen Research & Development, LLC
Phase 1
108
Chemnitz, Hamburg, Heidelberg, Würzburg
2024-06-07
Recruiting
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
NCT06319820Non-Muscle Invasive Bladder Neoplasms
DrugGemcitabine
Janssen Research & Development, LLC
Phase 3
641
Berlin, Braunschweig, Cologne, Dresden, Frankfurt am Main, Hamburg, Herne, Jena
2024-04-18
Active, closed
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
NCT06143878Plaque Psoriasis
DrugsIcotrokinra·Deucravacitinib
Janssen Research & Development, LLC
Phase 3
774
Berlin, Bramsche, Dresden, Düsseldorf, Hamburg, Kiel, Langenau, Leipzig
2024-01-17
Recruiting
A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
NCT05912517Hemolytic Disease of the Fetus and Newborn
DrugNipocalimab
Janssen Research & Development, LLC
Phase 3
120
Berlin, Giessen, Hamburg
2023-12-20
Active, closed
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
NCT06095102Plaque Psoriasis
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
311
Berlin, Bochum, Darmstadt, Dresden, Frankfurt am Main, Hamburg, Schwerin, Witten
2023-10-12
Active, closed
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515Relapsed or Refractory Multiple Myeloma
DrugsTeclistamab·Carfilzomib·Pomalidomide·Bortezomib
Janssen Research & Development, LLC
Phase 3
614
Cottbus, Dresden, Greifswald, Hamburg, Heidelberg, Marburg, Tübingen, Ulm
2023-03-29
Active, closed
A Study of Daratumumab
NCT05438043Multiple Myeloma
DrugsCarfilzomib·Pomalidomide·Daratumumab·Lenalidomide
Janssen Research & Development, LLC
Phase 3
213
Chemnitz, Hamburg, Tübingen
2022-12-15
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222Multiple Myeloma
DrugsTalquetamab·Teclistamab·Daratumumab·Lenalidomide
Janssen Research & Development, LLC
Phase 3
1,590
Berlin, Essen, Halle, Hamburg, Nuremberg, Tübingen, Würzburg
2022-10-25
Active, closed
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05455320Multiple Myeloma
DrugsTalquetamab·Pomalidomide·Daratumumab·Dexamethasone
Janssen Research & Development, LLC
Phase 3
864
Berlin, Cologne, Hamburg, Heidelberg, Leipzig, Mainz, Würzburg
2022-10-13
Recruiting
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
NCT05379595Advanced or Metastatic Colorectal Cancer
DrugsAmivantamab·Fluorouracil·Leucovorin·Irinotecan
Janssen Research & Development, LLC
Phase 1/2
225
Hamburg, Munich
2022-07-29
Active, closed
A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
NCT05338775Relapsed/ Refractory Multiple Myeloma
DrugsTalquetamab·Teclistamab
Janssen Research & Development, LLC
Phase 1
74
Dresden, Hamburg, Heidelberg, Würzburg
2022-05-25
Active, closed
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
NCT04988295Carcinoma, Non-Small-Cell Lung
DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin
Janssen Research & Development, LLC
Phase 3
776
Berlin, Hamburg, Heidelberg, Heilbronn, Leipzig, Moers, München, Recklinghausen
2021-11-17
Active, closed
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05083169Multiple Myeloma
DrugsTeclistamab·Pomalidomide·Bortezomib·Daratumumab
Janssen Research & Development, LLC
Phase 3
587
Dresden, Düsseldorf, Essen, Freiburg im Breisgau, Hamburg, Hamm, Heidelberg, Kiel
2021-10-14
Active, closed
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
NCT04929210Arthritis, Psoriatic
DrugsTremfya·Guselkumab
Janssen Research & Development, LLC
Phase 4
411
Berlin, Hamburg, Herne, Ratingen
2021-08-30
Active, closed
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
NCT04923893Multiple Myeloma
DrugsCilta-cel·Bortezomib·Lenalidomide·Fludarabine
Janssen Research & Development, LLC
Phase 3
743
Berlin, Dresden, Freiburg im Breisgau, Hamburg, Heidelberg, Leipzig, Mainz, München
2021-08-19
Active, closed
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
NCT04882098Arthritis, Psoriatic
DrugGuselkumab
Janssen Research & Development, LLC
Phase 3
1,054
Berlin, Hamburg, Herne, Magdeburg, Mainz, Ratingen
2021-06-17
Active, closed
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
NCT04181827Multiple Myeloma
DrugsCilta-cel·Pomalidomide·Bortezomib·Daratumumab
Janssen Research & Development, LLC
Phase 3
419
Cologne, Dresden, Hamburg, Leipzig, Tübingen, Würzburg
2020-06-12
Active, closed
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
NCT04108195Multiple Myeloma
DrugsTalquetamab·Teclistamab·Pomalidomide·Daratumumab
Janssen Research & Development, LLC
Phase 1
290
Freiburg im Breisgau, Hamburg, Heidelberg, Würzburg
2020-02-21
Active, closed
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
NCT04133636Multiple Myeloma
DrugsCilta-cel·Bortezomib·Daratumumab·Lenalidomide
Janssen Research & Development, LLC
Phase 2
208
Hamburg, Würzburg
2019-11-07
Active, closed
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
NCT03767244Prostatic Neoplasms
DrugApalutamide
Janssen Research & Development, LLC
Phase 3
2,517
Aachen, Braunschweig, Cologne, Eisleben Lutherstadt, Essen, Frankfurt am Main, Gronau, Hamburg
2019-06-11
Active, closed
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03466411Crohn's Disease
DrugsGuselkumab 1·Guselkumab 2·Guselkumab 3·Ustekinumab
Janssen Research & Development, LLC
Phase 2/3
1,409
Augsburg, Berlin, Dresden, Frankfurt, Frankfurt am Main, Hamburg, Hanover, Heidelberg
2018-04-13
Active, closed
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
NCT02365597Urothelial Cancer
DrugsErdafitinib·Midazolam·Metformin
Janssen Research & Development, LLC
Phase 2
239
Berlin, Erlangen, Essen, Freiburg im Breisgau, Göttingen, Greifswald, Hamburg, Hanover
2015-04-22
Rows per page Showing 1–33 of 33
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 29 September 2026. https://priyalifescience.com/clinical-trials-germany/city/hamburg

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 33 of those studies with a site in Hamburg that also match the filters currently applied.

How many clinical trials are recruiting in Hamburg?

13 of the 33 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 0 have not yet opened recruitment, 20 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hamburg), 33 studies
PhaseStudiesRecruitingShare
Phase 3231069.7%
Phase 1309.1%
Phase 2319.1%
Observational113%
Phase 1/2113%
Phase 2/3103%
Phase 4103%

Most active sponsors

Lead sponsors with the most studies (Hamburg)
Lead sponsorStudiesRecruiting
Janssen Research & Development, LLC3313
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.